On January 28, 2025, the Company received clearance of its IND from the FDA to initiate a first-in-human Phase 1 dose escalation clinical trial to evaluate one of its lead drug candidates, HCW9302, in ...

Session Date and Time: Monday, April 28, 2:00 - 5:00 p.m.

Certain subsets of immune NK cells were altered in the blood of people with ALS, and could serve as therapeutic targets, a ...